Media Archive
Search our media archive for news, events or related images on your topic.
| Content | |
|---|---|
| 20. November 2009 European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting ... more | |
| 20. November 2009 European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting ... more | |
Foto Bibliothek Production of MabThera and Avastin: vial separation turntable more | |
Foto Bibliothek ... more | |
Foto Bibliothek Bevacizumab (the antibody in the anti-tumour drug Avastin) is administered as an infusion. It is specialised in identifying ... more | |
Foto Bibliothek Avastin 100 mg vial, antiangiogenic therapy to demonstrate overall and/or progressionfree survival benefits in patients with ... more | |
Foto Bibliothek Production of Avastin (biotechnology) (cover Roche Half Year Report 2009) more | |
Foto Bibliothek Building 95, Roche Basel, production of Avastinmore | |
| 23. September 2009 New data presented at ECCO/ESMO confirms benefits of bevacizumab (Avastin) based therapy for the first-line treatment of metastatic breast cancer This update outlines data on bevacizumab in metastatic breast cancer presented at the joint ECCO 15 and ESMO 34 congress ... more | |
| 23. September 2009 From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases New data from several studies presented at ECCO 15 and ESMO 34 confirm unique benefits of Avastin (bevacizumab) and Xeloda ... more | |
| 23. September 2009 Roche announces results from two early studies which show promise for patients with malignant melanoma more | |
| 23. September 2009 Phase IV lung cancer study confirms the safety and outstanding efficacy benefit of Avastin-based therapy in a 'real world' setting This update outlines the key data from four presentations on Avastin in advanced non-small cell lung cancer (NSCLC) at the ... more | |
| 22. September 2009 Avastin could play an important role in improving the daily lives of patients with the most aggressive form of brain cancer Analysis of BRAIN study shows that patients may have a stabilisation or improvement in neurocognitive function and a reduction ... more | |
| 18. August 2009 Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a ... more | |
| 03. August 2009 Avastin approved in US for the most common type of kidney cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon ... more | |
| 29. Juli 2009 European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer more | |
| 30. Mai 2009 Maintenance treatment with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worsening more | |
| 30. Mai 2009 Full results from first Phase III study of Avastin in adjuvant colon cancer announced Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does ... more | |
| 29. May 2009 Avastin plus commonly used chemotherapies improves the time breast cancer patients live without their disease getting worse Results from the phase III RIBBON-1 study presented today at ASCO showed that patients with advanced HER2-negative breast ... more | |
| 06. Mai 2009 Important New Treatment Option Approved in US for Patients with the Most Aggressive Form of Brain Cancer Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) ... more | |
| 22. April 2009 Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy ... more | |
| 03. Februar 2009 Avastin and Tarceva in combination significantly improves the time patients with advanced lung cancer can live without their disease worsening Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer ... more | |
| 10. Dezember 2008 New data show that Herceptin, Xeloda and Avastin help patients with early and advanced breast cancer live longer or remain disease free for longer New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), ... more | |
| 24. November 2008 New phase III study of Avastin in advanced breast cancer meets its primary endpoint of increasing the time patients live without their disease getting worse Third study confirming the benefit of Avastin in breast cancer shows that Avastin can be effectively combined with commonly ... more | |
| 13. November 2008 Avastin gives an additional 4 months of life to patients with one of the most common types of lung cancer more | |
| 06. Oktober 2008 Roche announces topline outcomes for Avastin-Tarceva combination study in advanced lung cancer Phase III data shows evidence of potential benefit for patients with advanced lung cancer. Roche today announced topline ... more | |
| 31. May 2008 Study confirms that Avastin significantly increases chance of living without disease progression in metastatic breast cancer Avastin (bevacizumab), significantly improves the time patients with metastatic breast cancer live without their disease ... more | |
| Mediarelease, 2008/02/23 FDA grants accelerated approval of Avastin in combination with paclitaxel chemotherapy for first-line treatment of patients with advanced HER2-negative breast cancer Roche today announced that Genentech has received U.S. Food and Drug Administration (FDA) accelerated approval for Avastin(bevacizumab), ... more | |
| Mediarelease, 2008/02/13 Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint Roche announced today that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination ... more | |
| Mediarelease, 2008/01/28 Avastin receives broad label extension in Europe for the treatment of patients with metastatic colorectal cancer Many more patients can now benefit from Avastin's proven survival benefits. Roche announced today that the European ... more | |
| 19. December 2007 Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer Roche`s innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced ... more | |
| Mediarelease, 2007/11/16 Avastin receives positive opinion in Europe for first-line treatment of patients with advanced kidney cancer - Avastin offers patients the chance to live twice as long without their disease advancing - Avastin now recommended in ... more | |
| Mediarelease, 2007/08/24 Avastin approved in Europe for first-line treatment of patients with advanced lung cancer more | |
| Mediarelease, 2007/07/20 Avastin receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer more | |
| Mediarelease, 2007/06/04 Avastin significantly prolongs progression free survival in advanced kidney cancer more | |
| Mediarelease, 2007/04/18 Breakthrough cancer drug Avastin approved in Japan for use in advanced or recurrent colorectal cancer more | |
| Mediarelease, 2007/03/29 Avastin approved in Europe for first line treatment of women with metastatic breast cancer more | |
| Mediarelease, 2007/03/27 Roche submits application to the FDA for use of XELOX (Xeloda plus oxaliplatin) with or without Avastin for the treatment of advanced colorectal cancer more | |
| Mediarelease, 2007/02/26 Positive recommendation for Avastin use in advanced or recurrent colorectal cancer in Japan more | |
| Mediarelease, 2007/02/23 Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancer more | |
| Mediarelease, 2007/02/22 New phase III study confirms positive outcome of Avastin in patients with advanced lung cancer more | |
| Mediarelease, 2006/12/14 Landmark Study of Avastin in Lung Cancer Published Today in New England Journal of Medicine more | |
| 12. December 2006 Avastin shows positive outcomes in patients with advanced kidney cancer more | |
| 12. October 2006 Avastin approved in US for first-line treatment of most common form of lung cancer more | |
| Mediarelease, 2006/10/02 Avastin and Xeloda set new standards for the treatment of first line metastatic colorectal cancer more | |
| 08. August 2006 Avastin filed in Europe for treatment of most common form of lung cancer more | |
| Mediarelease, 2006/07/31 Avastin and Xeloda meet primary endpoints in large Phase III first line metastatic colorectal cancer study more | |
| 10. July 2006 Avastin filed in Europe for first-line treatment of women with advanced breast cancer more | |
| 27. June 2006 US Phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint more | |
| 26. May 2006 Avastin filed with FDA in US for treatment of women with advanced breast cancer more | |
| 21. April 2006 Chugai files innovative cancer medicine Avastin for fast approval in Japan more | |
| 12. April 2006 Avastin filed in US for treatment of most common form of lung cancer more | |
| Mediarelease, 2005/06/17 Revolutionary Treatment Avastin Helps People with Advanced Colorectal Cancer Live Longer While Preserving Their Quality of Life more | |
| 15. April 2005 Avastin produces significant benefit in first-line metastatic breast cancer Interim analysis shows improved progression-free survival with Avastin for patients with previously untreated metastatic ... more | |
| 15. March 2005 Revolutionary cancer treatment Avastin now proven to extend life also for lung cancer patients Interim analysis shows first ever positive results in untreated patients with a biological therapy for non-small cell lung ... more | |
| 14. January 2005 Innovative Roche cancer medicine Avastin approved in EU more | |
| 20. December 2004 Breakthrough cancer treatment Avastin approved in Switzerland more | |
| 30. November 2004 Unique cancer drug Avastin now shown to improve survival across different metastatic colorectal cancer regimens more | |
| 22. October 2004 Avastin receives positive opinion in Europe for the treatment of patients with metastatic colorectal cancer more | |
| Mediarelease, 2004/04/21 First quarter exceeds expectations: 15% rise in sales results in further market share gains; Avastin successfully launched in United States more | |
| Mediarelease, 2004/02/27 Breakthrough cancer treatment Avastin receives first approval in the US more | |
| 15. December 2003 Roche reports on two major achievements in Japan, the world´s second largest pharmaceuticals market Chugai and Roche sign licensing agreement for anti-cancer drugs Avastin and Omnitarg in Japan - Pegasys reimbursement achieved ... more | |
| 05. December 2003 Roche files marketing application for Avastin with European health authorities more | |
| 26. November 2003 Additional study with Avastin in metastatic colorectal cancer demonstrates a significant increase in progression-free survival Avastin plus chemotherapy also shows trend toward improvement in median survival - US FDA review and plans for filing Avastin ... more | |
| 08. July 2003 Roche acquires Avastin rights outside the U.S. from Genentech more |